首页> 外国专利> USE OF MARKERS IN THE IDENTIFICATION OF CARDIOTOXIC AGENTS AND IN THE DIAGNOSIS AND MONITORING OF CARDIOMYOPATHY AND CARDIOVASCULAR DISEASE

USE OF MARKERS IN THE IDENTIFICATION OF CARDIOTOXIC AGENTS AND IN THE DIAGNOSIS AND MONITORING OF CARDIOMYOPATHY AND CARDIOVASCULAR DISEASE

机译:标记物在识别心血管疾病中以及在诊断和监测心肌肌病和心血管疾病中的用途

摘要

The invention provides methods for the diagnosis and prognosis of cardiovascular disease, and for monitoring of the treatment of cardiovascular disease, including heart failure and cardiomyopathy. The invention further provides methods for identifying an agent for treating cardiomyopathy or heart failure, for identifying a cardiotoxic agent, and for identifying a rescue agent to reduce or prevent drug-induced toxicity, by using one or more biomarkers selelcted from the group consisting of CCDC47, HMOX1, PTX3, PAI1, IL27, IGFBP7, Emmprin, CFL2, EDIL3, NUCB1, PE D18:0-20:3/D18:1-20:2/D16:0-22:3; PE D18:0-22:5/D18:1-22:4; PE D16:1-22:6; PE P18:1-18:1/P18:0-18:2/P16:0-20:2; LPC 20:3; and PC-LI-183-D18:22-22:6, or any of the other biomarkers provided herein. The invention further provides kits for practicing the methods of the invention.
机译:本发明提供了用于心血管疾病的诊断和预后以及用于监测包括心力衰竭和心肌病在内的心血管疾病的治疗的方法。本发明进一步提供了通过使用选自CCDC47的一种或多种生物标记物来鉴定用于治疗心肌病或心力衰竭的药物,鉴定心脏毒性药物以及鉴定用于减轻或预防药物诱导的毒性的挽救药物的方法。 ,HMOX1,PTX3,PAI1,IL27,IGFBP7,Emprin,CFL2,EDIL3,NUCB1,PE D18:0-20:3 / D18:1-20:2 / D16:0-22:3; PE D18:0-22:5 / D18:1-22:4; PE D16:1-22:6; PE P18:1-18:1 / P18:0-18:2 / P16:0-20:2; LPC 20:3; PC-LI-183-D18:22-22:6,或本文提供的任何其他生物标记。本发明进一步提供了用于实施本发明方法的试剂盒。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号